Decisions and recommendations taken by the committee enjoy the highest level of credibility among the various bodies concerned, including the Ministry of Health, non-health government ministries and the private sector. The official terms of reference Selleck Erlotinib for the committee include: advising on the technical specifications for vaccines; advising on the standards and regulations for prescribing, providing, transporting and storing vaccines, both in the public and private health sectors; advising on the documents

and types of data to be collected on adverse events; and taking measures to avoid preventable, adverse events. They also specify that the committee advise on the significance of epidemiological or clinical studies submitted in support of these vaccines at their registration and thereafter, recommending policies for regulating the use of these vaccines in the Sultanate. The scope of the committee’s activities extends to vaccines and immunization as well as to other infectious diseases. It addresses these issues Modulators within the parameters of the Terms of Reference. Within Birinapant in vitro the area of vaccines and immunization, the committee decides on the use of new vaccines,

most recently the seven-valent pneumococcal conjugate vaccine (PCV-7), the inactivated poliovirus vaccine (IPV) and the Haemophilus influenzae type b conjugate-hepatitis-B-DTwP (pentavalent) vaccine. It has also recommended vaccination schedules for these vaccines and has furthermore made recommendations on vaccines for high-risk groups, including targeted immunization against seasonal influenza, meningococcal meningitis and rubella. Different formulations for the pentavalent vaccine have been considered, as have vaccines extending beyond infant schedules to all vaccine-preventable diseases. Finally, the committee has made recommendations on specific vaccines, commissioning to outside experts impact studies on hepatitis-B vaccination as well as

cost-effectiveness studies on the rotavirus and PCV-7 vaccines. Minutes of committee meetings and a record Dichloromethane dehalogenase of their recommendations are summarized and publicized on a regular basis in a national newsletter distributed to all health sector professionals, including physicians, members of the Ministry of Health and university researchers. The meetings themselves are closed. Committee members are appointed for a period of 3 years by the Minister of Health and may be re-appointed thereafter for another 3 years maximum. These appointments are made on the basis of nominations given by the Director General for Health Affairs (DGHA), the Director of the Department of Communicable Disease Surveillance and Control (DCDSC), the Chair and other committee members. There are also four ex officio members on the committee. They participate in the discussions that lead to the required consensus.